KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Castle Biosciences (CSTL) Accumulated Depreciation & Amortization (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Accumulated Depreciation & Amortization for 8 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 42.58% to $18.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.3 million through Dec 2025, up 42.58% year-over-year, with the annual reading at $18.3 million for FY2025, 42.58% up from the prior year.
  • Accumulated Depreciation & Amortization hit $18.3 million in Q4 2025 for Castle Biosciences, up from $16.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $18.3 million in Q4 2025 to a low of $867000.0 in Q2 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $8.4 million across 5 years, with a median of $7.6 million in 2022.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 670.47% in 2022 and later dropped 5.81% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $3.0 million in 2021, then skyrocketed by 157.99% to $7.8 million in 2022, then rose by 3.35% to $8.1 million in 2023, then soared by 58.22% to $12.8 million in 2024, then surged by 42.58% to $18.3 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for CSTL at $18.3 million in Q4 2025, $16.8 million in Q3 2025, and $15.5 million in Q2 2025.